🏷

Classifications

Harrison's Chapter

ICD-O Morphology

🔗

Mappings

MONDO

MONDO:0017844 Sezary syndrome

Primary MONDO disease identifier for this Sezary syndrome entry.

📘

Definitions

1

Diagnostic definition of Sezary syndrome

Sezary syndrome is the leukemic cutaneous T-cell lymphoma entity defined by erythroderma, generalized lymphadenopathy, and a circulating malignant CD4-positive T-cell population with Sezary-cell morphology and aberrant antigen loss.

CASE_DEFINITION Disease-level diagnostic definition of Sezary syndrome

Show evidence (1 reference)

PMID:34165432 SUPPORT Human Clinical

"The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."

This diagnostic study states the disease-defining triad and the characteristic aberrant circulating T-cell phenotype used to define Sezary syndrome.

⚙

Pathophysiology

7

Malignant central memory CD4-positive T-cell clone

The malignant Sezary cell population has a central-memory T-cell phenotype, consistent with a CD4-positive memory T-cell clone that recirculates between blood, skin, and lymph nodes.

central memory CD4-positive T cell link

Downstream

Skin- and lymph node-homing receptor program The malignant clone coexpresses trafficking receptors that support recirculation through blood, skin, and lymph nodes.

JAK/STAT pathway activation Recurrent signaling lesions enhance survival and proliferative fitness of the malignant clone.

PLCG1-driven T-cell receptor signaling TCR-proximal signaling lesions provide an additional activation and survival program.

Epigenetic regulator loss Recurrent chromatin-remodeling defects destabilize transcriptional control of malignant T cells.

Show evidence (1 reference)

PMID:20484084 SUPPORT Human Clinical

"Our results suggest that SS is a malignancy of central memory T cells and MF is a malignancy of skin resident effector memory T cells."

This phenotypic analysis directly supports central-memory T-cell identity as the disease cell of origin in Sezary syndrome.

Skin- and lymph node-homing receptor program

Malignant Sezary cells coexpress skin-homing and lymph-node-homing receptors, enabling dissemination between circulation, skin, and lymphoid tissues.

central memory CD4-positive T cell link

T cell migration link ↑ INCREASED

Downstream

Disseminated malignant T-cell accumulation Aberrant homing and recirculation support disease involvement of skin, blood, and lymph nodes.

Show evidence (1 reference)

PMID:15727636 SUPPORT Human Clinical

"Our results support the concept that chemokine receptors play an important role in the pathophysiology of SS and suggest that the malignant clone may represent an expansion of skin-homing cutaneous 'central' memory T cells in the peripheral blood of these patients."

This flow-cytometric study links the central-memory malignant clone to specific homing receptors that support the blood-skin-lymph-node distribution of Sezary cells.

JAK/STAT pathway activation

Recurrent activating lesions in JAK/STAT components create a survival and proliferation program in malignant Sezary cells and provide a rationale for pathway-targeted therapy.

cell surface receptor signaling pathway via JAK-STAT link ↑ INCREASED

Downstream

Disseminated malignant T-cell accumulation Activated cytokine signaling reinforces malignant T-cell survival and expansion.

Show evidence (1 reference)

PMID:26415585 SUPPORT Human Clinical

"We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."

This genomic study directly supports recurrent activation of JAK/STAT signaling as a core Sezary syndrome mechanism.

PLCG1-driven T-cell receptor signaling

Recurrent gain-of-function lesions in PLCG1 support aberrant T-cell receptor-proximal signaling in malignant Sezary cells.

T cell receptor signaling pathway link ↑ INCREASED

Downstream

Disseminated malignant T-cell accumulation Persistent T-cell receptor-proximal activation supports malignant T-cell fitness and persistence.

Show evidence (1 reference)

PMID:26415585 SUPPORT Human Clinical

"We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."

Recurrent gain-of-function PLCG1 mutations implicate abnormal T-cell receptor-proximal signaling as a distinct disease mechanism in Sezary syndrome.

Epigenetic regulator loss

Frequent loss-of-function lesions in chromatin-remodeling genes, especially ARID1A, disrupt transcriptional regulation in malignant Sezary cells.

Downstream

Disseminated malignant T-cell accumulation Epigenetic dysregulation cooperates with signaling lesions to stabilize malignant transcriptional programs.

Show evidence (1 reference)

PMID:26415585 SUPPORT Human Clinical

"We identify previously unknown recurrent loss-of-function aberrations targeting members of the chromatin remodelling/histone modification and trithorax families, including ARID1A in which functional loss from nonsense and frameshift mutations and/or targeted deletions is observed in 40.3% of SS genomes."

This genomic study supports chromatin-remodeling gene loss, especially ARID1A disruption, as a recurrent upstream mechanism in Sezary syndrome.

Disseminated malignant T-cell accumulation

Combined aberrant trafficking, survival signaling, and transcriptional dysregulation produce a high burden of malignant T cells in the blood, skin, and lymph nodes.

central memory CD4-positive T cell link

cell population proliferation link ↑ INCREASED

Downstream

Cell-mediated immunosuppression Advanced malignant T-cell burden is accompanied by a suppressive immune milieu and clinical immune dysfunction.

Show evidence (1 reference)

PMID:33072126 SUPPORT Human Clinical

"Sezary Syndrome (SS) represents a rare and aggressive variant of cutaneous T cell lymphoma (CTCL) with a life expectancy of less than 5 years, characterized by the co-presence of neoplastic lymphocytes mainly in the blood, lymph nodes and skin."

This longitudinal human study explicitly describes the defining anatomic distribution of malignant Sezary cells across blood, lymph nodes, and skin.

Cell-mediated immunosuppression

Sezary syndrome is accompanied by expanded suppressive T-cell populations that blunt effective antitumor and antimicrobial immune responses.

negative regulation of T cell mediated immunity link ↑ INCREASED

Show evidence (1 reference)

PMID:29204699 SUPPORT In Vitro

"We found elevations in Treg populations, across Treg subtypes, in patients with SzS, and these Treg markedly suppressed proliferation of autologous CD4+CD25- responder T cells."

Patient-derived functional studies support a suppressive T-cell milieu as a biologically relevant downstream mechanism in Sezary syndrome.

✶

Histopathology

2

Circulating Sezary cells

Diagnosis requires a circulating population of malignant Sezary cells with characteristic cerebriform T-cell morphology and aberrant CD4-dominant immunophenotype.

Show evidence (1 reference)

PMID:34165432 SUPPORT Human Clinical

"The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."

This diagnostic study supports high circulating Sezary-cell burden with characteristic antigen loss as a core morphologic and immunophenotypic hallmark.

Cerebriform lymphoid infiltrate

Skin biopsy commonly shows a band-like infiltrate of atypical lymphoid cells with cerebriform nuclei.

Show evidence (1 reference)

PMID:6651315 SUPPORT Human Clinical

"The most frequently noted histologic type was a lymphomatoid subepidermal band infiltrate, composed predominantly of atypical lymphoid cells with cerebriform nuclei, found in 53 (44%) of the skin biopsy specimens."

This clinicopathologic series directly supports cerebriform lymphocyte morphology as the most common histologic pattern in skin biopsies from Sezary syndrome.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

4

Cardiovascular 1

Lymphadenopathy Lymphadenopathy (HP:0002716)

Show evidence (1 reference)

PMID:34165432 SUPPORT Human Clinical

"The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."

This diagnostic definition explicitly identifies generalized lymphadenopathy as a defining Sezary syndrome manifestation.

Immune 1

Erythroderma Erythroderma (HP:0001019)

Show evidence (1 reference)

PMID:34165432 SUPPORT Human Clinical

"The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."

This diagnostic definition explicitly includes erythroderma as a core clinical feature of Sezary syndrome.

Integument 2

Pruritus Pruritus (HP:0000989)

Show evidence (1 reference)

PMID:31489115 SUPPORT Human Clinical

"Sézary syndrome (SS) is an aggressive cutaneous T cell lymphoma with pruritic skin inflammation and immune dysfunction, driven by neoplastic, clonal memory T cells in both peripheral blood and skin."

This human-sample transcriptomic study explicitly describes pruritic skin inflammation as part of the Sezary syndrome phenotype.

Palmoplantar keratoderma Palmoplantar keratoderma (HP:0000982)

Show evidence (1 reference)

PMID:29026585 SUPPORT Human Clinical

"Plantar keratoderma is usually pathognomonic for Sézary syndrome and clinicians should be alerted to its presence."

This case-based report highlights palmoplantar keratoderma as a clinically useful phenotype in Sezary syndrome.

🧬

Genetic Associations

4

ARID1A (Tumor Suppressor Loss)

Show evidence (1 reference)

PMID:26415585 SUPPORT Human Clinical

"We identify previously unknown recurrent loss-of-function aberrations targeting members of the chromatin remodelling/histone modification and trithorax families, including ARID1A in which functional loss from nonsense and frameshift mutations and/or targeted deletions is observed in 40.3% of SS genomes."

This genomic study directly supports recurrent ARID1A loss as a central tumor-suppressor lesion in Sezary syndrome.

PLCG1 (Gain of Function Mutation)

Show evidence (1 reference)

PMID:26415585 SUPPORT Human Clinical

"We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."

This directly supports recurrent PLCG1 gain-of-function mutations in Sezary syndrome.

JAK1 (Gain of Function Mutation)

Show evidence (1 reference)

PMID:26415585 SUPPORT Human Clinical

"We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."

This directly supports recurrent JAK1 activation as part of the Sezary syndrome JAK/STAT lesion spectrum.

STAT3 (Gain of Function Mutation)

Show evidence (1 reference)

PMID:26415585 SUPPORT Human Clinical

"We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."

This directly supports recurrent STAT3 activation within the Sezary syndrome JAK/STAT lesion spectrum.

💊

Treatments

5

Extracorporeal Photopheresis

Action: extracorporeal photopheresis Ontology label: Extracorporeal Photopheresis NCIT:C62729

Blood-directed extracorporeal photopheresis is a standard component of multimodality treatment for Sezary syndrome and can improve cutaneous and blood disease.

Show evidence (1 reference)

PMID:34478581 SUPPORT Human Clinical

"Most patients with SS and MF who underwent multimodality therapy with ECP had favorable cutaneous and blood response."

This real-world clinical study supports extracorporeal photopheresis as an active blood- and skin-directed treatment in Sezary syndrome.

Bexarotene

Action: pharmacotherapy MAXO:0000058

Agent: bexarotene ↗

Oral rexinoid therapy remains an established systemic option for advanced or refractory cutaneous T-cell lymphoma, including Sezary syndrome.

Show evidence (1 reference)

PMID:11331325 SUPPORT Human Clinical

"Bexarotene is orally administered, safe, and generally well tolerated with reversible side effects, and is effective for the treatment of advanced, refractory CTCL."

This phase II-III study supports bexarotene as an effective systemic therapy for advanced CTCL, the disease class that includes Sezary syndrome.

Mogamulizumab

Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: mogamulizumab ↗

CCR4-directed monoclonal antibody therapy has particular activity in blood-involved cutaneous T-cell lymphoma and is highly relevant to Sezary syndrome.

Mechanism Target:

INHIBITS Skin- and lymph node-homing receptor program — Mogamulizumab targets CCR4-expressing malignant T cells and counteracts the trafficking/survival program associated with the Sezary-cell central-memory phenotype.

Show evidence (1 reference)

PMID:25605368 SUPPORT Human Clinical

"This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal antibody, in 41 pretreated patients with cutaneous T-cell lymphoma."

Clinical activity of an anti-CCR4 antibody supports CCR4-positive malignant T cells as a therapeutically actionable component of Sezary syndrome biology.

Show evidence (1 reference)

PMID:25605368 SUPPORT Human Clinical

"Among 38 evaluable patients, the overall response rate was 36.8%: 47.1% in Sézary syndrome (n = 17) and 28.6% in mycosis fungoides (n = 21)."

This phase 1/2 study directly demonstrates clinical activity of mogamulizumab in a Sezary syndrome subgroup.

Pembrolizumab

Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: pembrolizumab ↗

PD-1 blockade has meaningful activity in advanced relapsed or refractory MF/SS and provides a rational option when systemic immune-targeted therapy is needed.

Mechanism Target:

INHIBITS Cell-mediated immunosuppression — PD-1 blockade aims to reverse dysfunctional antitumor immunity in the immunosuppressive Sezary syndrome milieu.

Show evidence (1 reference)

PMID:31532724 SUPPORT Human Clinical

"Pembrolizumab demonstrated significant antitumor activity with durable responses and a favorable safety profile in patients with advanced MF/SS."

Clinical activity of PD-1 blockade supports immune dysfunction as a therapeutically relevant downstream mechanism in Sezary syndrome.

Show evidence (1 reference)

PMID:31532724 SUPPORT Human Clinical

"Pembrolizumab demonstrated significant antitumor activity with durable responses and a favorable safety profile in patients with advanced MF/SS."

This phase II study supports pembrolizumab as an active systemic immunotherapy for advanced MF/SS, including Sezary syndrome.

Allogeneic hematopoietic stem cell transplantation

Action: allogeneic hematopoietic stem cell transplantation Ontology label: Allogeneic Hematopoietic Stem Cell Transplantation NCIT:C46089

Allogeneic transplantation is the main potentially curative option for selected fit patients with advanced or multiply relapsed Sezary syndrome.

Show evidence (1 reference)

PMID:25068422 SUPPORT Human Clinical

"Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free."

This multicenter transplant cohort supports allogeneic hematopoietic cell transplantation as a durable disease-control option in advanced MF/SS.

🔬

Biochemical Markers

2

High circulating Sezary cell count

Show evidence (1 reference)

PMID:34165432 SUPPORT Human Clinical

"The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."

This supports high circulating Sezary-cell burden as a disease-defining biomarker used in diagnosis and blood involvement assessment.

KIR3DL2-positive circulating tumor T cells

Show evidence (1 reference)

PMID:31487384 SUPPORT Human Clinical

"The presence of KIR3DL2+ Sézary cells (SCs) ≥ 200 μL-1 correlated with the diagnosis of SS, with sensitivity of 88·6% and specificity of 96·3%."

This prospective diagnostic study supports KIR3DL2-positive Sezary cells as a specific biomarker for Sezary syndrome and blood tumor burden.

{ }

Source YAML

click to show

name: Sezary Syndrome
creation_date: "2026-04-13T05:29:21Z"
updated_date: "2026-04-22T20:13:21Z"
category: Cancer
categories:
- Hematologic Malignancy
- T-cell Neoplasm
- Cutaneous T-cell Lymphoma
synonyms:
- Sezary syndrome
- Sézary syndrome
- Sezary disease
- Sézary disease
- Sezary lymphoma
- SS
disease_term:
  preferred_term: Sezary syndrome
  term:
    id: MONDO:0017844
    label: Sezary syndrome
description: >-
  Sezary syndrome is an aggressive leukemic form of cutaneous T-cell lymphoma
  defined by erythroderma, generalized lymphadenopathy, and a high burden of
  circulating malignant CD4-positive T cells with cerebriform morphology.
  Disease biology is consistent with a skin-homing central memory T-cell clone
  with recurrent JAK/STAT and PLCG1 signaling lesions, frequent chromatin
  remodeling defects including ARID1A loss, and marked immune dysfunction.
  Modern management uses blood-directed and systemic approaches such as
  extracorporeal photopheresis, bexarotene, mogamulizumab, checkpoint
  inhibition, and in selected cases allogeneic hematopoietic stem cell
  transplantation.
parents:
- cutaneous T-cell lymphoma
- T-cell lymphoma
definitions:
- name: Diagnostic definition of Sezary syndrome
  definition_type: CASE_DEFINITION
  description: >-
    Sezary syndrome is the leukemic cutaneous T-cell lymphoma entity defined by
    erythroderma, generalized lymphadenopathy, and a circulating malignant
    CD4-positive T-cell population with Sezary-cell morphology and aberrant
    antigen loss.
  scope: Disease-level diagnostic definition of Sezary syndrome
  evidence:
  - reference: PMID:34165432
    reference_title: "[Use of the multiparametric panel CD3/CD4/CD8/CD7/CD26/CD158k in the detection and use of flow cytometry of Sezary cells]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."
    explanation: This diagnostic study states the disease-defining triad and the characteristic aberrant circulating T-cell phenotype used to define Sezary syndrome.
epidemiology:
- name: Nationwide incidence in Finland
  description: Sezary syndrome is a rare lymphoma with an average incidence of 0.02 per 100,000 persons in Finland.
  unit: cases per 100,000 persons
  evidence:
  - reference: PMID:41508834
    reference_title: "Incidence and Mortality of Mycosis Fungoides and Sezary Syndrome: A Nationwide Registry Study in Finland."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The average incidence of MF was 0.38 and of SS 0.02 per 100,000 persons in 2007-2019 and was highest among older adults."
    explanation: This nationwide registry study provides a contemporary population-level incidence estimate for Sezary syndrome.
pathophysiology:
- name: Malignant central memory CD4-positive T-cell clone
  description: >-
    The malignant Sezary cell population has a central-memory T-cell phenotype,
    consistent with a CD4-positive memory T-cell clone that recirculates between
    blood, skin, and lymph nodes.
  cell_types:
  - preferred_term: central memory CD4-positive T cell
    term:
      id: CL:0000904
      label: central memory CD4-positive, alpha-beta T cell
  evidence:
  - reference: PMID:20484084
    reference_title: "Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results suggest that SS is a malignancy of central memory T cells and MF is a malignancy of skin resident effector memory T cells."
    explanation: This phenotypic analysis directly supports central-memory T-cell identity as the disease cell of origin in Sezary syndrome.
  downstream:
  - target: Skin- and lymph node-homing receptor program
    description: The malignant clone coexpresses trafficking receptors that support recirculation through blood, skin, and lymph nodes.
  - target: JAK/STAT pathway activation
    description: Recurrent signaling lesions enhance survival and proliferative fitness of the malignant clone.
  - target: PLCG1-driven T-cell receptor signaling
    description: TCR-proximal signaling lesions provide an additional activation and survival program.
  - target: Epigenetic regulator loss
    description: Recurrent chromatin-remodeling defects destabilize transcriptional control of malignant T cells.
- name: Skin- and lymph node-homing receptor program
  description: >-
    Malignant Sezary cells coexpress skin-homing and lymph-node-homing receptors,
    enabling dissemination between circulation, skin, and lymphoid tissues.
  cell_types:
  - preferred_term: central memory CD4-positive T cell
    term:
      id: CL:0000904
      label: central memory CD4-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: T cell migration
    modifier: INCREASED
    term:
      id: GO:0072678
      label: T cell migration
  evidence:
  - reference: PMID:15727636
    reference_title: "Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results support the concept that chemokine receptors play an important role in the pathophysiology of SS and suggest that the malignant clone may represent an expansion of skin-homing cutaneous 'central' memory T cells in the peripheral blood of these patients."
    explanation: This flow-cytometric study links the central-memory malignant clone to specific homing receptors that support the blood-skin-lymph-node distribution of Sezary cells.
  downstream:
  - target: Disseminated malignant T-cell accumulation
    description: Aberrant homing and recirculation support disease involvement of skin, blood, and lymph nodes.
- name: JAK/STAT pathway activation
  description: >-
    Recurrent activating lesions in JAK/STAT components create a survival and
    proliferation program in malignant Sezary cells and provide a rationale for
    pathway-targeted therapy.
  biological_processes:
  - preferred_term: cell surface receptor signaling pathway via JAK-STAT
    modifier: INCREASED
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
  evidence:
  - reference: PMID:26415585
    reference_title: "Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."
    explanation: This genomic study directly supports recurrent activation of JAK/STAT signaling as a core Sezary syndrome mechanism.
  downstream:
  - target: Disseminated malignant T-cell accumulation
    description: Activated cytokine signaling reinforces malignant T-cell survival and expansion.
- name: PLCG1-driven T-cell receptor signaling
  description: >-
    Recurrent gain-of-function lesions in PLCG1 support aberrant T-cell receptor-proximal
    signaling in malignant Sezary cells.
  biological_processes:
  - preferred_term: T cell receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0050852
      label: T cell receptor signaling pathway
  evidence:
  - reference: PMID:26415585
    reference_title: "Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."
    explanation: Recurrent gain-of-function PLCG1 mutations implicate abnormal T-cell receptor-proximal signaling as a distinct disease mechanism in Sezary syndrome.
  downstream:
  - target: Disseminated malignant T-cell accumulation
    description: Persistent T-cell receptor-proximal activation supports malignant T-cell fitness and persistence.
- name: Epigenetic regulator loss
  description: >-
    Frequent loss-of-function lesions in chromatin-remodeling genes, especially ARID1A,
    disrupt transcriptional regulation in malignant Sezary cells.
  evidence:
  - reference: PMID:26415585
    reference_title: "Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identify previously unknown recurrent loss-of-function aberrations targeting members of the chromatin remodelling/histone modification and trithorax families, including ARID1A in which functional loss from nonsense and frameshift mutations and/or targeted deletions is observed in 40.3% of SS genomes."
    explanation: This genomic study supports chromatin-remodeling gene loss, especially ARID1A disruption, as a recurrent upstream mechanism in Sezary syndrome.
  downstream:
  - target: Disseminated malignant T-cell accumulation
    description: Epigenetic dysregulation cooperates with signaling lesions to stabilize malignant transcriptional programs.
- name: Disseminated malignant T-cell accumulation
  description: >-
    Combined aberrant trafficking, survival signaling, and transcriptional dysregulation
    produce a high burden of malignant T cells in the blood, skin, and lymph nodes.
  cell_types:
  - preferred_term: central memory CD4-positive T cell
    term:
      id: CL:0000904
      label: central memory CD4-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:33072126
    reference_title: "Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sezary Syndrome (SS) represents a rare and aggressive variant of cutaneous T cell lymphoma (CTCL) with a life expectancy of less than 5 years, characterized by the co-presence of neoplastic lymphocytes mainly in the blood, lymph nodes and skin."
    explanation: This longitudinal human study explicitly describes the defining anatomic distribution of malignant Sezary cells across blood, lymph nodes, and skin.
  downstream:
  - target: Cell-mediated immunosuppression
    description: Advanced malignant T-cell burden is accompanied by a suppressive immune milieu and clinical immune dysfunction.
- name: Cell-mediated immunosuppression
  description: >-
    Sezary syndrome is accompanied by expanded suppressive T-cell populations that
    blunt effective antitumor and antimicrobial immune responses.
  biological_processes:
  - preferred_term: negative regulation of T cell mediated immunity
    modifier: INCREASED
    term:
      id: GO:0002710
      label: negative regulation of T cell mediated immunity
  evidence:
  - reference: PMID:29204699
    reference_title: "Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We found elevations in Treg populations, across Treg subtypes, in patients with SzS, and these Treg markedly suppressed proliferation of autologous CD4+CD25- responder T cells."
    explanation: Patient-derived functional studies support a suppressive T-cell milieu as a biologically relevant downstream mechanism in Sezary syndrome.
histopathology:
- name: Circulating Sezary cells
  finding_term:
    preferred_term: Sezary-cell morphology
    term:
      id: HP:0025461
      label: Abnormal cell morphology
  diagnostic: true
  description: >-
    Diagnosis requires a circulating population of malignant Sezary cells with
    characteristic cerebriform T-cell morphology and aberrant CD4-dominant
    immunophenotype.
  evidence:
  - reference: PMID:34165432
    reference_title: "[Use of the multiparametric panel CD3/CD4/CD8/CD7/CD26/CD158k in the detection and use of flow cytometry of Sezary cells]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."
    explanation: This diagnostic study supports high circulating Sezary-cell burden with characteristic antigen loss as a core morphologic and immunophenotypic hallmark.
- name: Cerebriform lymphoid infiltrate
  finding_term:
    preferred_term: cerebriform lymphoid infiltrate
    term:
      id: HP:0025461
      label: Abnormal cell morphology
  diagnostic: true
  description: >-
    Skin biopsy commonly shows a band-like infiltrate of atypical lymphoid cells
    with cerebriform nuclei.
  evidence:
  - reference: PMID:6651315
    reference_title: "Sézary syndrome. A clinicopathologic study of 39 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequently noted histologic type was a lymphomatoid subepidermal band infiltrate, composed predominantly of atypical lymphoid cells with cerebriform nuclei, found in 53 (44%) of the skin biopsy specimens."
    explanation: This clinicopathologic series directly supports cerebriform lymphocyte morphology as the most common histologic pattern in skin biopsies from Sezary syndrome.
phenotypes:
- category: Dermatologic
  name: Erythroderma
  description: >-
    Generalized erythematous scaling skin involvement is one of the defining clinical
    manifestations of classic Sezary syndrome.
  diagnostic: true
  phenotype_term:
    preferred_term: erythroderma
    term:
      id: HP:0001019
      label: Erythroderma
  evidence:
  - reference: PMID:34165432
    reference_title: "[Use of the multiparametric panel CD3/CD4/CD8/CD7/CD26/CD158k in the detection and use of flow cytometry of Sezary cells]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."
    explanation: This diagnostic definition explicitly includes erythroderma as a core clinical feature of Sezary syndrome.
- category: Lymphatic
  name: Lymphadenopathy
  description: >-
    Generalized lymph node enlargement is part of the classic diagnostic triad of Sezary syndrome.
  diagnostic: true
  phenotype_term:
    preferred_term: lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  evidence:
  - reference: PMID:34165432
    reference_title: "[Use of the multiparametric panel CD3/CD4/CD8/CD7/CD26/CD158k in the detection and use of flow cytometry of Sezary cells]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."
    explanation: This diagnostic definition explicitly identifies generalized lymphadenopathy as a defining Sezary syndrome manifestation.
- category: Dermatologic
  name: Pruritus
  description: >-
    Severe itch is a prominent manifestation and contributes substantially to symptom burden.
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  evidence:
  - reference: PMID:31489115
    reference_title: "Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sézary syndrome (SS) is an aggressive cutaneous T cell lymphoma with pruritic skin inflammation and immune dysfunction, driven by neoplastic, clonal memory T cells in both peripheral blood and skin."
    explanation: This human-sample transcriptomic study explicitly describes pruritic skin inflammation as part of the Sezary syndrome phenotype.
- category: Dermatologic
  name: Palmoplantar keratoderma
  description: >-
    Marked palmoplantar hyperkeratosis is a recognized clinical clue that can point
    toward Sezary syndrome.
  phenotype_term:
    preferred_term: palmoplantar keratoderma
    term:
      id: HP:0000982
      label: Palmoplantar keratoderma
  evidence:
  - reference: PMID:29026585
    reference_title: "Plantar keratoderma of Sézary syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plantar keratoderma is usually pathognomonic for Sézary syndrome and clinicians should be alerted to its presence."
    explanation: This case-based report highlights palmoplantar keratoderma as a clinically useful phenotype in Sezary syndrome.
biochemical:
- name: High circulating Sezary cell count
  biomarker_term:
    preferred_term: Sezary cell count
    term:
      id: NCIT:C74625
      label: Sezary Cell Count
  notes: >-
    High circulating Sezary-cell burden is central to diagnosis and blood tumor-burden
    assessment in Sezary syndrome.
  evidence:
  - reference: PMID:34165432
    reference_title: "[Use of the multiparametric panel CD3/CD4/CD8/CD7/CD26/CD158k in the detection and use of flow cytometry of Sezary cells]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 109/L characterized by a CD4+/CD8- phenotype with loss of one or more T antigens (mainly CD7 and/or CD26)."
    explanation: This supports high circulating Sezary-cell burden as a disease-defining biomarker used in diagnosis and blood involvement assessment.
- name: KIR3DL2-positive circulating tumor T cells
  biomarker_term:
    preferred_term: KIR3DL2 positive
    term:
      id: NCIT:C171048
      label: KIR3DL2 Positive
  notes: >-
    KIR3DL2 positivity improves diagnostic specificity and helps quantify blood tumor burden,
    especially in patients with lymphopenia or ambiguous CD7/CD26 results.
  evidence:
  - reference: PMID:31487384
    reference_title: "Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presence of KIR3DL2+ Sézary cells (SCs) ≥ 200 μL-1 correlated with the diagnosis of SS, with sensitivity of 88·6% and specificity of 96·3%."
    explanation: This prospective diagnostic study supports KIR3DL2-positive Sezary cells as a specific biomarker for Sezary syndrome and blood tumor burden.
genetic:
- name: ARID1A
  association: Tumor Suppressor Loss
  gene_term:
    preferred_term: ARID1A
    term:
      id: hgnc:11110
      label: ARID1A
  notes: >-
    ARID1A loss-of-function lesions are recurrent in Sezary syndrome and indicate
    a major chromatin-remodeling branch of disease pathogenesis.
  evidence:
  - reference: PMID:26415585
    reference_title: "Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identify previously unknown recurrent loss-of-function aberrations targeting members of the chromatin remodelling/histone modification and trithorax families, including ARID1A in which functional loss from nonsense and frameshift mutations and/or targeted deletions is observed in 40.3% of SS genomes."
    explanation: This genomic study directly supports recurrent ARID1A loss as a central tumor-suppressor lesion in Sezary syndrome.
- name: PLCG1
  association: Gain of Function Mutation
  gene_term:
    preferred_term: PLCG1
    term:
      id: hgnc:9065
      label: PLCG1
  notes: >-
    Gain-of-function PLCG1 mutations implicate aberrant T-cell receptor-proximal
    signaling in malignant Sezary cells.
  evidence:
  - reference: PMID:26415585
    reference_title: "Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."
    explanation: This directly supports recurrent PLCG1 gain-of-function mutations in Sezary syndrome.
- name: JAK1
  association: Gain of Function Mutation
  gene_term:
    preferred_term: JAK1
    term:
      id: hgnc:6190
      label: JAK1
  notes: >-
    JAK1 is one of the recurrently mutated JAK/STAT pathway genes in Sezary syndrome;
    the same study also identified JAK3, STAT3, and STAT5B lesions.
  evidence:
  - reference: PMID:26415585
    reference_title: "Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."
    explanation: This directly supports recurrent JAK1 activation as part of the Sezary syndrome JAK/STAT lesion spectrum.
- name: STAT3
  association: Gain of Function Mutation
  gene_term:
    preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  notes: >-
    STAT3 is a recurrently altered downstream effector in the JAK/STAT pathway lesion spectrum of Sezary syndrome.
  evidence:
  - reference: PMID:26415585
    reference_title: "Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%)."
    explanation: This directly supports recurrent STAT3 activation within the Sezary syndrome JAK/STAT lesion spectrum.
diagnosis:
- name: Peripheral blood flow cytometry with KIR3DL2, CD7, and CD26 assessment
  description: >-
    Flow cytometric quantification of aberrant circulating CD4-positive T cells,
    especially with inclusion of KIR3DL2, improves sensitivity and specificity of
    Sezary syndrome diagnosis and blood staging.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:31487384
    reference_title: "Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "KIR3DL2 expression on T cells is highly specific and helps the early diagnosis of SS, especially in those patients with lymphopenia."
    explanation: This prospective study supports multiparameter flow cytometry with KIR3DL2 as a high-specificity diagnostic strategy in Sezary syndrome.
- name: Blood T-cell receptor clonality testing
  description: >-
    Molecular assessment of clonal T-cell receptor rearrangement in blood helps
    establish blood involvement and is recommended when early or nonerythrodermic
    Sezary syndrome is suspected.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:28709694
    reference_title: "Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early SS should be considered in cases of nonerythrodermic dermatitis that is refractory to conventional treatments. In these cases, examination of the blood by PCR for monoclonal T-cell receptor rearrangement and by flow cytometry to identify an expanded or aberrant T-cell population should be considered."
    explanation: This multicenter cohort study explicitly recommends blood T-cell receptor clonality testing together with flow cytometry when early Sezary syndrome is suspected.
treatments:
- name: Extracorporeal Photopheresis
  description: >-
    Blood-directed extracorporeal photopheresis is a standard component of multimodality
    treatment for Sezary syndrome and can improve cutaneous and blood disease.
  treatment_term:
    preferred_term: extracorporeal photopheresis
    term:
      id: NCIT:C62729
      label: Extracorporeal Photopheresis
  evidence:
  - reference: PMID:34478581
    reference_title: "Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients with SS and MF who underwent multimodality therapy with ECP had favorable cutaneous and blood response."
    explanation: This real-world clinical study supports extracorporeal photopheresis as an active blood- and skin-directed treatment in Sezary syndrome.
- name: Bexarotene
  description: >-
    Oral rexinoid therapy remains an established systemic option for advanced or refractory cutaneous T-cell lymphoma, including Sezary syndrome.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: bexarotene
      term:
        id: NCIT:C1635
        label: Bexarotene
  evidence:
  - reference: PMID:11331325
    reference_title: "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bexarotene is orally administered, safe, and generally well tolerated with reversible side effects, and is effective for the treatment of advanced, refractory CTCL."
    explanation: This phase II-III study supports bexarotene as an effective systemic therapy for advanced CTCL, the disease class that includes Sezary syndrome.
- name: Mogamulizumab
  description: >-
    CCR4-directed monoclonal antibody therapy has particular activity in blood-involved
    cutaneous T-cell lymphoma and is highly relevant to Sezary syndrome.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: mogamulizumab
      term:
        id: NCIT:C62510
        label: Mogamulizumab
  evidence:
  - reference: PMID:25605368
    reference_title: "Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among 38 evaluable patients, the overall response rate was 36.8%: 47.1% in Sézary syndrome (n = 17) and 28.6% in mycosis fungoides (n = 21)."
    explanation: This phase 1/2 study directly demonstrates clinical activity of mogamulizumab in a Sezary syndrome subgroup.
  target_mechanisms:
  - target: Skin- and lymph node-homing receptor program
    treatment_effect: INHIBITS
    description: >-
      Mogamulizumab targets CCR4-expressing malignant T cells and counteracts the
      trafficking/survival program associated with the Sezary-cell central-memory phenotype.
    evidence:
    - reference: PMID:25605368
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal antibody, in 41 pretreated patients with cutaneous T-cell lymphoma."
      explanation: Clinical activity of an anti-CCR4 antibody supports CCR4-positive malignant T cells as a therapeutically actionable component of Sezary syndrome biology.
- name: Pembrolizumab
  description: >-
    PD-1 blockade has meaningful activity in advanced relapsed or refractory MF/SS
    and provides a rational option when systemic immune-targeted therapy is needed.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: pembrolizumab
      term:
        id: NCIT:C106432
        label: Pembrolizumab
  evidence:
  - reference: PMID:31532724
    reference_title: "Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pembrolizumab demonstrated significant antitumor activity with durable responses and a favorable safety profile in patients with advanced MF/SS."
    explanation: This phase II study supports pembrolizumab as an active systemic immunotherapy for advanced MF/SS, including Sezary syndrome.
  target_mechanisms:
  - target: Cell-mediated immunosuppression
    treatment_effect: INHIBITS
    description: >-
      PD-1 blockade aims to reverse dysfunctional antitumor immunity in the immunosuppressive
      Sezary syndrome milieu.
    evidence:
    - reference: PMID:31532724
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pembrolizumab demonstrated significant antitumor activity with durable responses and a favorable safety profile in patients with advanced MF/SS."
      explanation: Clinical activity of PD-1 blockade supports immune dysfunction as a therapeutically relevant downstream mechanism in Sezary syndrome.
- name: Allogeneic hematopoietic stem cell transplantation
  description: >-
    Allogeneic transplantation is the main potentially curative option for selected
    fit patients with advanced or multiply relapsed Sezary syndrome.
  treatment_term:
    preferred_term: allogeneic hematopoietic stem cell transplantation
    term:
      id: NCIT:C46089
      label: Allogeneic Hematopoietic Stem Cell Transplantation
  evidence:
  - reference: PMID:25068422
    reference_title: "Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free."
    explanation: This multicenter transplant cohort supports allogeneic hematopoietic cell transplantation as a durable disease-control option in advanced MF/SS.
classifications:
  icdo_morphology:
    classification_value: Lymphoma
    evidence:
    - reference: PMID:15727636
      reference_title: "Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "OBJECTIVES: To investigate the expression of CCR4, CCR7 and CCR10 on skin-homing CLA(+) and CD4(+) T cells in the peripheral blood of patients with Sezary syndrome (SS), a rare leukaemic variant of cutaneous T-cell lymphoma."
      explanation: This primary human study explicitly classifies Sezary syndrome as a leukemic variant of cutaneous T-cell lymphoma, supporting lymphoma morphology.
  harrisons_chapter:
  - classification_value: cancer
    evidence:
    - reference: PMID:26415585
      reference_title: "Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Sézary syndrome (SS) is an aggressive leukaemia of mature T cells with poor prognosis and limited options for targeted therapies."
      explanation: This primary genomic study supports Sezary syndrome as a malignant T-cell cancer.
  - classification_value: hematologic malignancy
    evidence:
    - reference: PMID:26415585
      reference_title: "Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Sézary syndrome (SS) is an aggressive leukaemia of mature T cells with poor prognosis and limited options for targeted therapies."
      explanation: This primary genomic study supports Sezary syndrome as a hematologic malignancy with mature T-cell leukemic behavior.
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0017844
      label: Sezary syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for this Sezary syndrome entry.

📚

References & Deep Research

Deep Research

1

OpenAI ▸

Sezary Syndrome Deep Research Notes

Modeling decisions

Per cancer curation guidance from dismech issue #1198, this curation treats Sezary syndrome as a single disease-level mechanism graph rather than trying to make every ontology child or staging bucket its own dismech page.
disease_term is MONDO-first: MONDO:0017844 Sezary syndrome.
NCIT grounding was added wherever the current schema supports cancer-specific terms directly: disease-context term NCIT:C3366 Sezary Syndrome, parent context NCIT:C3467 Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, histopathology findings such as NCIT:C36722 Sezary Cell and NCIT:C39621 Cerebriform Lymphocyte, biomarker NCIT:C74625 Sezary Cell Count, biomarker NCIT:C171048 KIR3DL2 Positive, and oncology-specific intervention terms such as NCIT:C62729 Extracorporeal Photopheresis and NCIT:C46089 Allogeneic Hematopoietic Stem Cell Transplantation.
I did not create separate disorder files for nonerythrodermic Sezary syndrome, B-stage strata, or large-cell transformation. Those are presentation, staging, or progression facets, not separate disease-level causal programs.
I therefore omitted has_subtypes in the YAML. For this disease slice, adding pseudo-subtypes would have created ontology noise without improving the mechanism graph.

Disease identity and ontology grounding

MONDO disease anchor: MONDO:0017844 Sezary syndrome.
NCIT disease grounding for cancer curation context: NCIT:C3366 Sezary Syndrome.
NCIT parent disease context: NCIT:C3467 Primary Cutaneous T-Cell Non-Hodgkin Lymphoma.
Core cell-type grounding used in the graph: CL:0000904 central memory CD4-positive, alpha-beta T cell.
Core biological-process grounding used in the graph:
GO:0072678 T cell migration
GO:0007259 cell surface receptor signaling pathway via JAK-STAT
GO:0050852 T cell receptor signaling pathway
GO:0008283 cell population proliferation
GO:0002710 negative regulation of T cell mediated immunity

Key literature takeaways used in the YAML

Definition and diagnosis

PMID:34165432 gives the operational disease-defining triad and the classic circulating CD4+/CD8- phenotype with loss of CD7 and/or CD26.
PMID:31487384 shows that KIR3DL2 materially improves early diagnosis and blood staging, especially in lymphopenic patients.
PMID:28709694 argues that early Sezary syndrome can be missed when erythroderma is absent and supports blood PCR for monoclonal T-cell receptor rearrangement plus flow cytometry in suspicious refractory dermatitis.

Cell of origin and trafficking biology

PMID:20484084 supports the central-memory T-cell model for Sezary syndrome and contrasts it with mycosis fungoides.
PMID:15727636 anchors the skin/blood/lymph-node recirculation program through CCR4, CCR10, and CCR7.

Core oncogenic mechanisms

PMID:26415585 is the main disease-genomics anchor for this entry:
recurrent ARID1A loss and broader chromatin-remodeling defects
recurrent PLCG1 gain-of-function mutations
recurrent JAK1, JAK3, STAT3, and STAT5B lesions
explicit therapeutic rationale for JAK/STAT pathway inhibition
PMID:29204699 supports downstream immune dysfunction through expanded suppressive T-cell populations in Sezary syndrome.

Histopathology and phenotype

PMID:6651315 supports the classic skin-biopsy pattern of atypical lymphoid cells with cerebriform nuclei.
PMID:31489115 supports pruritic inflammatory disease burden and immune dysfunction in a modern human-sample transcriptomic study.
PMID:29026585 supports palmoplantar keratoderma as a clinically useful Sezary clue.

Therapy

PMID:34478581 supports extracorporeal photopheresis as a blood- and skin-active treatment in real-world SS/MF practice.
PMID:11331325 supports oral bexarotene as effective systemic CTCL therapy.
PMID:25605368 supports mogamulizumab, with stronger response rates in Sezary syndrome than in mycosis fungoides and especially strong blood responses.
PMID:31532724 supports pembrolizumab activity in advanced relapsed/refractory MF/SS.
PMID:25068422 supports allogeneic hematopoietic cell transplantation as the main potentially curative option in advanced MF/SS.

Important research not fully promoted into the YAML graph

PMID:38170178 shows that Staphylococcus aureus enterotoxins can induce drug resistance in primary malignant T cells from patients with Sezary syndrome through TCR, NF-kappaB, and JAK/STAT-associated programs. I kept this in research notes instead of making it a core disease node because it is a clinically important resistance modifier, but not the cleanest disease-defining upstream program for the base Sezary syndrome graph.
PMID:25802883 reports a CTLA4:CD28 fusion in an advanced Sezary syndrome case with rapid clinical response to ipilimumab. This is mechanistically interesting but currently better treated as a rare precision-oncology exception than as a disease-level canonical node.
PMID:25981000 and PMID:28709694 support nonerythrodermic/early Sezary presentations. Per #1198, these were not split into a separate disease file because they are presentation variants rather than a separate causal program.

Expected validation-sensitive points

The triad and blood-burden snippets use typography from PubMed abstracts, including the multiplication sign and micro symbol; these should be preserved exactly for reference validation.
NCIT disease-level mappings were handled through schema-supported NCIT uses (findings, biomarkers, treatment terms, agents) plus this research note because the current DiseaseMappings container only exposes explicit mondo_mappings, not ncit_mappings.

Sezary Syndrome

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Source YAML

References & Deep Research

Deep Research

Sezary Syndrome Deep Research Notes

Modeling decisions

Disease identity and ontology grounding

Key literature takeaways used in the YAML

Definition and diagnosis

Cell of origin and trafficking biology

Core oncogenic mechanisms

Histopathology and phenotype

Therapy

Important research not fully promoted into the YAML graph

Expected validation-sensitive points